228 related articles for article (PubMed ID: 9726093)
1. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Goldberg RM; Erlichman C
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093
[TBL] [Abstract][Full Text] [Related]
2. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.
Khayat D; Gil-Delgado M; Antoine EC; Coeffic D; Benhammouda A; Grapin JP; Bastian G
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):64-7. PubMed ID: 9726094
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
Grem JL
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
[TBL] [Abstract][Full Text] [Related]
6. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
Lavrenkov K; Man S; Mermershtain W; Cohen Y
J Chemother; 2002 Feb; 14(1):84-7. PubMed ID: 11892905
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan: toward clinical end points in drug development.
Pazdur R
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the use of irinotecan in colorectal cancer.
Cunningham D; Maroun J; Vanhoefer U; Van Cutsem E
Oncologist; 2001; 6 Suppl 4():17-23. PubMed ID: 11585970
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Van Cutsem E; Blijham GH
Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
12. North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.
O'Connell MJ
Semin Oncol; 2001 Feb; 28(1 Suppl 1):4-8. PubMed ID: 11273589
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan in the treatment of colorectal cancer: clinical overview.
Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
Zaniboni A
J Clin Oncol; 1997 Jun; 15(6):2432-41. PubMed ID: 9196159
[TBL] [Abstract][Full Text] [Related]
16. Update on European adjuvant trials with irinotecan for colorectal cancer.
Douillard JY; Barbarot V; Bennouna J
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):13-5. PubMed ID: 12014862
[TBL] [Abstract][Full Text] [Related]
17. [Recent advance in chemotherapy for advanced colorectal cancer].
Aiba K
Gan To Kagaku Ryoho; 1996 Apr; 23(5):535-48. PubMed ID: 8678510
[TBL] [Abstract][Full Text] [Related]
18. US pivotal studies of irinotecan in colorectal carcinoma.
Pitot HC
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091
[TBL] [Abstract][Full Text] [Related]
19. Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.
Surguladze D; Steiner P; Prewett M; Tonra JR
Methods Mol Biol; 2010; 602():235-52. PubMed ID: 20012402
[TBL] [Abstract][Full Text] [Related]
20. Fluorouracil-based combinations in the treatment of metastatic breast cancer.
Klaassen U; Wilke H; Harstrick A; Seeber S
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):31-5. PubMed ID: 9516601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
